Method for treating a patient having a mutation in the extracellular domain of epidermal growth factor receptor (EGFR) using a combination of three fully human monoclonal anti-EGFR antibodies

摘要

In this specification, a combination of oligoclonal anti-epidermal growth factor receptor (anti-EGFR) antibodies (eg, a first monoclonal antibody (P1X), a second monoclonal antibody (P2X), and a third monoclonal antibody is used in a human patient. Human epithelial growth factor receptor (EGFR) extracellular domain (ECD) by administering MM-151) comprising ) Provide a method of treating mutant cancer. In one embodiment, the cancer comprises at least one mutation in the extracellular domain of EGFR selected from the group consisting of EGFR R451C, S464L, K467T, G465R, G465E, I491M, and S492R.